

निवासा आभयक तिवारी न 11  
जुलाई 2022 को महाराजपुर थाने में  
रिपोर्ट दर्ज कराई थी। इसमें कहा था  
कि उसके पिता राजेश तिवारी 10

आधार पर फाट 7 प्रचारा, 2025  
राजू और मनोज को हत्या के प्रयास  
का दोषी मानकर सजा सुनाई। काला  
और करन को दोषसिद्ध करार दिया।

प्रभारी हनुमंत विहार के अनुसार,  
पति-पत्नी के बीच झगड़े के बाद  
आत्महत्या की बात सामने आई है।

## JAGRAN PRAKASHAN LIMITED

CIN-L22219UP1975PLC004147

Registered Office: Jagran Building, 2, Sarvodaya Nagar, Kanpur-208005  
Tel: +91 512 2216161 Website: www.jplcorp.in, E-mail: investor@jagran.com

### Extract of Unaudited Consolidated Financial Results for the Quarter and Half-year ended September 30, 2025

(Rs in Lakhs, except per share data)

Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Half-year Ended	Half-year Ended	Year Ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total income from operations (net)	46,736.07	46,005.23	44,650.85	92,741.30	89,062.70	1,88,813.14
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	7,103.28	9,023.08	6,232.99	16,126.36	11,973.75	13,632.50
Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items and share of net profit / (loss) of Associates)	7,113.80	9,036.61	6,234.39	16,150.41	11,989.86	13,661.31
Net Profit / (Loss) for the period after Tax	5,693.77	6,676.07	4,164.66	12,369.84	8,268.11	9,393.46
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	5,758.42	6,676.07	4,157.74	12,434.49	8,261.19	9,076.04
Paid up Equity Share Capital (Face value Rs. 2/- per share)	4,353.09	4,353.09	4,353.09	4,353.09	4,353.09	4,353.09
Earnings Per Share (Face value of Rs. 2/- each) (not annualized)						
- Basic	2.69	3.09	1.97	5.78	3.86	6.02
- Diluted	2.69	3.09	1.97	5.78	3.86	6.02

#### Notes:

- The above is an extract of the detailed format of quarter / half-year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of quarter and half-year ended Financial Results, the pertinent disclosures have been made and are available on the websites of the Stock Exchanges i.e. www.nseindia.com and www.bseindia.com and also available on the Company's website at www.jplcorp.in.
- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 6, 2025 and has been subject to limited review of the statutory auditors of the Company.
- Summary of Key Unaudited Standalone Financial Results is as follows:

Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Half-year Ended	Half-year Ended	Year Ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total revenue from operations	41,377.14	39813.14	37,575.75	81,190.28	74,620.37	1,58,983.96
Profit before Tax	7,778.71	9473.10	6,909.36	17,251.81	12,865.87	28,783.71
Profit after Tax	6,172.75	7134.53	4,736.53	13,307.28	9,134.35	21,111.61
Total Comprehensive income	6,172.75	7134.53	4,736.53	13,307.28	9,134.35	20,837.24

Scan QR Code for complete financial results



For Jagran Prakashan Limited  
Sd/-  
Mahendra Mohan Gupta  
(Non-Executive Chairman)

Date: 06-11-2025  
Place: Kanpur

लाइव प्रसारण DD NEWS

सूचना एवं जनसम्पर्क विभाग, उत्तर प्रदेश



दिनांक

'वन्दे मातरम्'

- स्वतंत्रता आंदोलन
- ब्रिटिश सत्ता को उखाड़ने
- विभाजन के विरोध में हुए आंदोलन
- स्वदेशी आंदोलन
- 'वन्दे मातरम्' का प्रसिद्ध गायन कोलकाता में हुआ
- भारत के प्रथम राष्ट्रपति राजीव गांधी ने राष्ट्रीय चेतना को स्वीकार कर

# Sun Pharma's growth pill coated with innovation

Specialty portfolio powers Q2; Ilumya, Leqselvi, Unloxyt to anchor next phase

RAM PRASAD SAHU  
Mumbai, 6 November



India's largest pharmaceutical company, Sun Pharmaceutical Industries, reported a strong revenue performance for the July-September quarter (Q2) of 2025-26 (FY26), driven by key segments and geographies. Better than expected margins and lower research and development spending lifted operational performance. With a robust product pipeline and sustained growth momentum across markets, several brokerages have upgraded the stock, while others have maintained their 'buy' ratings.


Revenue for the quarter rose 8.6 per cent year-on-year (Y-o-Y), ahead of estimates, led by India (up 11 per cent) and the Rest of the World market (up 23 per cent). The US generics business continues to weigh on overall performance, but this was offset by 16 per cent growth in the global innovative medicines (specialty) portfolio.

Apart from pricing pressure on the generic version of blood cancer drug Revlimid, the company highlighted price erosion in other base business products as well. It remains uncertain when pricing conditions will stabilise.

The standout performance came from the global innovative portfolio, which grew 16.4 per cent Y-o-Y and 7 per cent sequentially. In the US, innovative medicine sales surpassed generics for the first time in Q2FY26. Elara Securities said that the launch of flagship product Ilumya — used to treat plaque psoriasis — in newer markets is helping offset slowing growth in the US, where the product is maturing.

Other contributors to the innovative portfolio included Cequa (for dry eyes) and the acne formulation Winlevi. The firm recently

## Stock health check



expects it to contribute \$110-125 million over FY26F (F: Forecast) through to 2026-27 (FY27). In addition, the planned launch of Unloxyt in the second half of FY26F (potential revenue: \$50-70 million over FY26F-FY27) and dossier filings in the European Union are expected to further strengthen the franchise.

The long-awaited launch of Ilumya for psoriatic arthritis by end-FY26 should further bolster overall Ilumya sales. Together, these products are expected to offset the Revlimid cliff and generate about \$200 million in incremental US revenue. Given the superior margin profile of innovative medicines, analyst Yogesh Soni of InCred expects margin expansion to begin from FY27. The brokerage has upgraded the stock to 'accumulate' and raised its target price to ₹2,000 from ₹1,900.

Motilal Oswal, however, has trimmed its FY26-28 earnings estimates by 3-6 per cent, factoring in higher marketing expenses for global innovative medicines and a higher tax rate. It has nevertheless maintained a 'buy' rating, with a target price of ₹1,960. Analysts led by Tushar Manudhane said Sun continues to strengthen its branded portfolio across both developed and emerging markets. Product launches and deeper market penetration are expected to sustain the company's strong growth trajectory, keeping it ahead of largecap peers in the Indian pharma space.

launched the hair loss drug Leqselvi and plans to introduce the skin cancer therapy Unloxyt soon. Analysts at Elara Securities, led by Bino Pathiparampil, believe these acquired products can help sustain growth in Sun's innovative segment, with each expected to generate over \$200 million in sales within three to four years.

The brokerage has raised its FY26 through to 2027-28 (FY28) core earnings per share estimates by 4-5 per cent and increased its target price from ₹1,871 to ₹1,968 per share. InCred Equities also expects the innovative portfolio — which has delivered 23 per cent annual growth over the past five years — to maintain momentum in the medium term, supported by a strong launch pipeline.

Sun introduced Leqselvi in the US during Q2 of 2024-25 and



## ALGO TRADING

# Trade with multiple stop-losses, risk limits

HIMALI PATEL

Securities & Exchange Board of India (Sebi) Chairman Tuhin Kanta Pandey said recently that the rise of algorithmic trading brings efficiency but also demands robust risk controls and real-time monitoring. Here is a look at the key risks retail investors face in algo trading and how they can manage them.

### Myriad risks

Liquidity is a major concern. Many stocks and options in India are illiquid, with shallow market depth and wide bid-ask spreads. Orders may not get filled or may execute at worse than expected prices, which is called slippage. "Slippage becomes a major issue if liquidity is not factored in," says Rajesh Ganesh, founder & chief executive officer (CEO), TripleInt Trading Systems.

Retail investors may also rely excessively on back-tested results or use poorly coded strategies. "Lack of real-time monitoring can cause significant losses if something goes wrong," says Vikas Singhania, chief executive officer (CEO), TradeSmart. Black-swan events can worsen losses. "Inad-

### Key dos and don'ts

- Do paper trading, or live runs with small amounts of capital
- Understand algo's logic, risk controls, and fallback mechanisms
- Scale based on profits, not to recover losses
- Don't jump between systems after a small loss or drawdown
- Don't ignore updates or assume the algo will handle all market conditions
- Control emotions, track performance daily and keep refining the strategy

equate stop-loss settings can trigger rapid drawdowns," says Harsh Vira, chief financial planner & founder, FinPro Wealth.

### Don't rely blindly on back-tested results

Back-tests often fail to reflect real-world trading. Strategies that excel in back tests often fail in live trading. "A reliable back test must include realistic costs, slippage, and drawdowns," says Vira. Short testing periods, cherry-

picked timeframes and mismatched conditions are red flags. "An algo performing well in a bullish phase may wipe out capital in a flat or negative market," says Ramakrishnan Selvaraj, cofounder, coin-hunt.bot. Investors should also examine peak-to-trough drawdowns and how long recovery took. One-off large profits or losses skewing results are red flags. Unrealistic outcomes are another warning sign. "A 100 per cent win rate or an extremely high Sharpe ratio is a red flag," says Singhania.

### Watch out for operational risks

Tech failures, connectivity issues, API disruptions, broker downtime, exchange outages and order rejections can all disrupt execution. They can lead to missed entries or exits. Reliability of infrastructure also matters. "Retail investors should avoid Excel-based trading," says Selvaraj. Instead, use a stable and tested platform, ideally cloud-based or broker-hosted. "Hedged strategies help cap maximum risk even if the algo cannot execute due to technical issues," says Ganesh.

### Manage risks

Algo trading should be segregated in a separate account with only risk capital deployed. Selvaraj recommends three layers of stop-losses — position-level, portfolio-level and maximum stop-loss. Traders should also implement pre-trade, daily, weekly and monthly risk limits. "If any limit is breached, reduce position size or switch to paper trading," says Ganesh.

Traders should not deploy all their capital in algo trading. They should maintain reserves for margin calls. Position sizing must

be disciplined. Avoid allocating more than a fixed percentage of capital to a single trade. Diversification also helps. "Use diversified strategies and test them in paper trading before going live," says Vira.

### Control costs

Algo platforms focus on building profitable strategies, but it is the investor's job to account for real-world costs. "Costs can be so large that even an algo with a positive edge may lose money," says Ganesh. "Too many trades — especially in options and futures — can lead to high brokerage, commissions and taxes, turning a profitable algo negative in the investor's account," says Selvaraj. "Slippage, impact cost (which increases for large orders in illiquid stocks), subscription and infrastructure costs (VPS, API, platform fees) must be factored in," says Singhania.

According to Vira, such costs can reduce real profits by 20-40 per cent compared to back tests, so simulations should be carried out before going live.

### Robust monitoring required

Monitoring should ideally be real-time or at least every 15-30 minutes. "Set up auto-alerts via short message service (SMS), email, or app notifications for drawdown breaches, margin shortfalls, or order failures," says Singhania.

Traders should review an end-of-day summary of profits and losses, open positions and system health. They should also maintain a manual override or kill switch. Retail algos can also be supervised via automated dashboards.

The writer is a Mumbai-based independent writer

# Porting health insurance? Here's what you should watch out for

Health insurance portability allows you to move from one insurer to another without losing accrued benefits, such as waiting period credits. But experts caution that poor timing, incomplete paperwork, or non-disclosure of health details can derail the process, leaving you exposed to fresh waiting periods or even policy lapses.

### Don't wait till the last moment

"One of the mistakes customers make while porting is to wait until their policy is about to expire," says Siddharth Singhal, head of health insurance at Policybazaar. If there's any break in the policy period, for example, if the grace period lapses before the new insurer issues the policy, customers may lose their continuity benefits.

### When porting makes sense

- Porting is ideal when your current policy no longer fits your needs, and you want to retain waiting period benefits.
- It is particularly useful when upgrading from ₹5 lakh to ₹10 lakh coverage or when moving to an insurer with stronger hospital tie-ups and smoother claims service.
- It also makes sense if your insurer

has hiked premiums significantly "without enhancing benefits" or if the new insurer offers better claim settlement ratios, customer service.

### Avoiding rejections

Rejections occur due to incomplete disclosures/high perceived health risk. Red flags include advanced age, multiple hospitalisations, or undisclosed pre-existing conditions.

Read full report here: [mybs.in/2erZiI](https://mybs.in/2erZiI)

COMPILED BY AMIT KUMAR

**In fast or fragile markets, insight brings perspective.**

Decode market moves with sharp, fast, expert analysis — every day with Stocks in the News in Business Standard.

To book your copy, SMS reaches to 57575 or email [order@bsmail.in](mailto:order@bsmail.in)

**Business Standard**  
Insight Out

**THE ASKA COOPERATIVE SUGAR INDUSTRIES LTD.**  
P.O. Nuagam (Aska) - 761111, Ganjam District, Odisha  
E-mail: [askasugar@yahoo.co.in](mailto:askasugar@yahoo.co.in)  
GSTIN : 21AAAT5989L120

**TENDER CALL NOTICE**

No. PUR/1734 Date : 06.11.2025

The Aska Cooperative Sugar Industries Ltd. at Nuagam, Aska in Ganjam District of Odisha state invites sealed Quotations from Manufacturer/Dealers/Supplier having GSTIN for supply of VFD, ABB AC centrifuge pane 200KW and 125KVA DG (100KW) Mame Cummins. Parties are requested to give their offer with detail terms & conditions. Please visit our website [www.askasugar.com](http://www.askasugar.com) for details of the Tender Call Notice.

**Managing Director**

**TATA POWER DELHI DISTRIBUTION LIMITED**  
A Tata Power and Delhi Government Joint Venture  
TATA POWER-DDL Regd. Office: NDPL House, Hudson Lines, Kingsway Camp, Delhi-110 009  
CIN No. U40109DL2001PLC111526, Website: [tatapower-ddl.com](http://tatapower-ddl.com)

**NOTICE INVITING TENDERS** Nov 07, 2025

TATA Power-DDL invites tenders as per following details:

Tender Enquiry No. / Work Description	Estimated Cost/EMD (Rs.)	Availability of Bid Document	Last Date & Time of Bid Submission/ Date and time of Opening of bids
TPDDL/ENG/ENQ/200001881/25-26 2 Yr RC for Supply of Precast DT Plinths Slab Type at TPDDL	1.52 Crs/ 1.89 Lac	07.11.2025	27.11.2025; 1300 Hrs/ 27.11.2025; 1330 Hrs
TPDDL/ENG/ENQ/200001882/25-26 RC for supply of 33 KV Cables with Returnable drums at TPDDL Site/Store.	4.92 Crs/ 9.39 Lac	07.11.2025	28.11.2025; 1500 Hrs/ 28.11.2025; 1530 Hrs

Complete tender and corrigendum document is available on our website [www.tatapower-ddl.com](http://www.tatapower-ddl.com) → Vendor Zone → Tender / Corrigendum Documents

**DIAGEO**  
India  
Corporate Identity Number: L01551KA1999PLC024991  
Regd. Office: 'UB Tower', # 24, Vittal Mallya Road, Bengaluru - 560 001, Karnataka, India.  
Tel: +91 80 2221 0705 | Fax: +91 80 2225 5253  
Email: [investor.india@diageo.com](mailto:investor.india@diageo.com) | Website: [www.diageoindia.com](http://www.diageoindia.com)

**NOTICE OF LOSS OF SHARE CERTIFICATES**

Notice is hereby given that the Company has received requests from the following shareholder(s) for issuance of Letter of Confirmation in lieu of Original Share Certificate(s) reported to have been lost/misplaced. The share certificate(s) mentioned hereunder are therefore deemed to be cancelled and no transactions thereon would be recognized by the Company:

Sl. No	Folio No.	Name of the Shareholder	No. of Shares	Certificate Number	Distinctive Nos
01	MS070927	ROHINI BHALCHANDRA KAMBLE	500	2723	721278811 - 721279310

The public are hereby advised against dealing in any way with the above share certificates. Any person(s) who has/ have any claim(s) in respect of the said share certificates are requested to lodge such claim(s) along with all documentary evidences with the Company at its Registered Office within 7 (seven) days of publication of this notice, after which no claim(s) will be entertained, and the Company shall proceed to issue a Letter of Confirmation in accordance with applicable SEBI regulations.

For **UNITED SPIRITS LIMITED**  
Sd/-  
**Pragya Kaul**  
Company Secretary and Compliance Officer

Place : Bengaluru  
Dated : November 06, 2025

**JAGRAN PRAKASHAN LIMITED**  
CIN-L22219UP1975PLC004147  
Registered Office: Jagran Building, 2, Sarvodaya Nagar, Kanpur-208005  
Tel: +91 512 2216161 Website: [www.jplicorp.in](http://www.jplicorp.in), E-mail: [investor@jagran.com](mailto:investor@jagran.com)

**Extract of Unaudited Consolidated Financial Results for the Quarter and Half-year ended September 30, 2025**  
(Rs in Lakhs, except per share data)

Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Half-year Ended	Half-year Ended	Year Ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total income from operations (net)	46,736.07	46,005.23	44,650.85	92,741.30	89,062.70	1,88,813.14
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	7,103.28	9,023.08	6,232.99	16,126.36	11,973.75	13,632.50
Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items and share of net profit / (loss) of Associates)	7,113.80	9,036.61	6,234.39	16,150.41	11,989.86	13,661.31
Net Profit / (Loss) for the period after Tax	5,693.77	6,676.07	4,164.66	12,369.84	8,268.11	9,393.46
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	5,758.42	6,676.07	4,157.74	12,434.49	8,261.19	9,076.04
Paid up Equity Share Capital (Face value Rs. 2/- per share)	4,353.09	4,353.09	4,353.09	4,353.09	4,353.09	4,353.09
Earnings Per Share (Face value of Rs. 2/- each) (not annualized)						
- Basic	2.69	3.09	1.97	5.78	3.86	6.02
- Diluted	2.69	3.09	1.97	5.78	3.86	6.02

**Notes:**

- The above is an extract of the detailed format of quarter / half-year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of quarter and half-year ended Financial Results, the pertinent disclosures have been made and are available on the websites of the Stock Exchanges i.e. [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and also available on the Company's website at [www.jplicorp.in](http://www.jplicorp.in).
- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 6, 2025 and has been subject to limited review of the statutory auditors of the Company.
- Summary of Key Unaudited Standalone Financial Results is as follows:

Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Half-year Ended	Half-year Ended	Year Ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total revenue from operations	41,377.14	39,813.14	37,575.75	81,190.28	74,620.37	1,58,983.96
Profit before Tax	7,778.71	9,473.10	6,909.36	17,251.81	12,865.87	28,783.71
Profit after Tax	6,172.75	7,134.53	4,736.53	13,307.28	9,134.35	21,111.61
Total Comprehensive income	6,172.75	7,134.53	4,736.53	13,307.28	9,134.35	20,837.24

Scan QR Code for complete financial results

For Jagran Prakashan Limited  
Sd/-  
**Mahendra Mohan Gupta**  
(Non-Executive Chairman)

Date: 06-11-2025  
Place: Kanpur

**BAJAJ HOUSING FINANCE LIMITED**  
CIN: L65910PN2008PLC132228 | Registered Office: Bajaj Auto Limited Complex, Mumbai-Pune Road, Akurdi, Pune - 411 035  
Corporate Office: 5th Floor, B2 Building, Cerebrum IT Park, Kumar City, Kalyani Nagar, Pune 411014.  
Tel.: 020-71878060 | E-mail: [bfhinvestor.service@bajajhousing.co.in](mailto:bfhinvestor.service@bajajhousing.co.in) | Website: [www.bajajhousingfinance.in](http://www.bajajhousingfinance.in)

**Extract of unaudited financial results for the Quarter and Half year ended 30 September 2025**  
(₹ in crore)

Sr. No.	Particulars	Quarter Ended 30.09.2025 (Unaudited)	Half Year Ended 30.09.2025 (Unaudited)	Quarter Ended 30.09.2024 (Unaudited)
1	Revenue from operations	2,754.85	5,370.56	2,410.15
2	Profit before tax	832.66	1,589.60	707.59
3	Profit after tax	642.96	1,226.26	545.60
4	Total comprehensive income (Comprising profit for the period and other comprehensive income after tax)	627.38	1,215.23	550.82
5	Paid-up equity share capital	8,328.61	8,328.61	8,328.15
6	Other equity as shown in Balance Sheet of the previous year			11,618.65
7	Earnings per share (Face value of ₹10/- each) (not annualised)			
	a. Basic (₹)	0.77	1.47	0.69
	b. Diluted (₹)	0.77	1.47	0.69

**Notes:**

The above is an extract of the unaudited financial results for the quarter and half year ended 30 September 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 6 November 2025 and subjected to limited review by joint statutory auditors and filed with the stock exchange under Regulation 33 and 52 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. These financial results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time and other recognised accounting practices generally accepted in India along with the circulars, guidelines and directions issued by the Reserve Bank of India (RBI) and the National Housing Bank (NHB) from time to time. The full format of the aforesaid financial results is available on the website of the Company, BSE Limited and National Stock Exchange of India Limited i.e. [www.bajajhousingfinance.in](http://www.bajajhousingfinance.in) and [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively. The same can be accessed by scanning the QR code provided below.

By order of the Board of Directors  
For **Bajaj Housing Finance Limited**  
**Atul Jain**  
Managing Director  
DIN: 09561712

**BAJAJ** FINSERV  
Pune  
6 November 2025